Выбор редакции
24 декабря 2017, 15:18

The top 10 Senate races of 2018

Democrats have the momentum, but Republicans are still favored to hold the chamber because of a favorable map.

22 декабря 2017, 17:31

Победа Трампа. Налоговая реформа в США спасет миллиарды инвестиций

Администрация президента США празднует налоговую победу. Хедж-фондам тоже стоило бы, хотя они могут лишиться возможности налогового маневра

19 декабря 2017, 18:04

Teva's Migraine Candidate Gets Priority Review From FDA

Teva's (TEVA) biologics license application (BLA) seeking approval for fremanezumab as a preventive treatment for migraine gets priority review from FDA

19 декабря 2017, 13:01

‘I Was An Easy Pickup’: How Trump Lost Manchin on Taxes

Red-state Democrats like the West Virginia senator should have been putty in the president’s hands. Instead, he’s alienated them to the point that he’s neither feared nor loved.

Выбор редакции
18 декабря 2017, 19:11

Bullish Inverse Head & Shoulder breakout in play?

Some stocks don’t have much to brag about over the past couple of years and below we look at one of them! Mylan (MYL) has had a rough go of it the past two years as it lost nearly 50% of its value. During this decline could a pattern opportunity have formed. Possibly! Below looks at MYL over the past 5-years- CLICK ON CHART TO ENLARGE Over the past year, MYL could be forming a bullish inverse head & shoulders pattern with a test of the neckline and falling resistance taking place at (1). If a breakout takes place here, it could attract buyers to this hard-hit stock. Another thing that catches our attention is the large unfilled gap that took place back in 2015 at the $65 zone. Often times “Gaps” end up getting filled. If this gap would get filled, MYL would make some nice gains from current levels. Full Disclosure- Members are long this stock with a tight stop.   Chart pattern analysis with brief commentary:    There is a ton of news and opinions about markets and stocks that make the decision-making process more difficult than it needs to be.     I believe the Power of the chart Pattern provides all you need to see what is taking place in an asset and determine the action to take.   This approach has worked well for me and our clients and I encourage you to test it for yourself.    Send an email if you would like to see sample research and take me up on a30 DAY FREE TEST DRIVE of our Premium or Weekly Research where I provide actionable alerts on breakouts and reversals in broad market indices, sectors, commodities, the miners and select individual stocks   Email [email protected]   Call us Toll free 877-721-7217 international 714-941-9381    Website: KIMBLECHARTINGSOLUTIONS.COM    Receive daily research I post on the blog each day   Follow on Twitter    See our latest webinar              

16 декабря 2017, 00:52

Mylan Announces IPR Proceedings for Sanofi's Lantus Patents

Mylan (MYL) announced that interpartes review (IPR) proceedings has been initiated by PTAB regarding two Orange Book-listed patents, U.S. Patent Nos. 7,476,652 and 7,713,930 owned by Sanofi.

Выбор редакции
08 декабря 2017, 15:40

Pharma Stock Roundup: FDA Nod for NVO's Ozempic, Second Indication for Lilly's Taltz

FDA approval for Novo Nordisk's (NVO) type II diabetes drug, a second indication for Lilly's Taltz, and the approval of the first Herceptin biosimilar were the key highlights this week.

Выбор редакции
04 декабря 2017, 17:46

Mylan Up on FDA Approval & Amazon's Rumored Pharmacy Interest

Mylan (MYL) receives approval for its biosimilar of breast cancer drug, Herceptin. Amazon is reportedly in talks with Mylan and another generic manufacturer about a potential entry in distribution of drugs.

Выбор редакции
04 декабря 2017, 17:32

Amazon (AMZN) May Sell Drugs if Reports Are to be Believed

Per reports, Amazon.com Inc. (AMZN) might venture into the prescription drug territory.

04 декабря 2017, 16:21

Will the Healthcare Landscape Change with the $69B CVS-Aetna Deal?

Will the $69 billion CVS Health (CVS)-Aetna acquisition trigger more such deals in the healthcare sector?

Выбор редакции
02 декабря 2017, 01:58

3 Drug/Biotech Stocks in Focus on World AIDS Day

On World AIDS Day, we look into some of the key pharma companies in the HIV market that are developing drugs to address the life threatening disease.

Выбор редакции
Выбор редакции
01 декабря 2017, 17:33

Cancer Space Update: Pfizer's Bavencio Fails in Phase III

The only major development in the cancer space this week was the failure of Pfizer's (PFE) Bavencio in a phase III gastric cancer study.

01 декабря 2017, 14:00

Pharma Stock Roundup: Pfizer/Merck KGaA Drug Fails in Study, Teva CEO Announces Changes

Key highlights this week include changes announced by Teva's CEO and Pfizer (PFE)/Merck KGaA's data presentation. Reports about Amazon's plans to enter the drug market also made headlines.

Выбор редакции
30 ноября 2017, 17:19

Glaxo Stock Down So Far This Year: Is a Reversal in Store?

Glaxo's shares have declined 7.9% this year so far.